Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes

Original Article ↗ Hacker News Discussion ↗

Early observational research suggests that semaglutide (Ozempic), a GLP‑1 diabetes and weight-loss drug, may significantly reduce Alzheimer’s risk in people with type 2 diabetes compared with other treatments, especially insulin. Commenters weigh how much of the effect might simply come from weight loss and better metabolic control versus a direct neuroprotective action, and note the lack of randomized trials and long‑term safety data. The thread broadens into debate over GLP‑1 drugs’ costs, side effects, potential use for addictions and other conditions, and whether pharmacological appetite control is an appropriate response to the obesity crisis.

Study Findings and Mechanism Questions

  • Summary: Semaglutide users with Type 2 diabetes showed substantially lower Alzheimer’s risk vs other diabetes drugs, especially insulin (70% lower risk).
  • Several commenters ask whether the effect is from semaglutide itself or from indirect effects: weight loss, reduced caloric intake, or improved glucose control.
  • Some note that similar benefits might not extend to thin, metabolically healthy people; others point out ongoing trials in non-obesity conditions (Alzheimer’s, Parkinson’s, addiction, NASH, PCOS, CVD).
  • The idea of Alzheimer’s as “type 3 diabetes” is raised, but one commenter pushes back on that framing.

Causality, Confounding, and Evidence Quality

  • Concerns about non-randomized, retrospective EHR analysis: selection bias (e.g., people closer to Alzheimer’s onset might be less likely to seek or get semaglutide).
  • Calls for more randomized, disease-focused trials and independent replication before strong conclusions.
  • One commenter flatly calls the publication “bogus” and points to broader uncertainty in Alzheimer’s research.

Benefits, Side Effects, and Long‑Term Risk

  • Enthusiastic group: GLP‑1s are described as potentially “the most important drug of our lifetime,” with large effects on obesity, diabetes, cardiovascular risk, and possibly addictions.
  • Personal anecdotes:
    • Major weight loss with reduced “food noise” and easier “intuitive eating.”
    • Dramatic reduction or cessation of heavy alcohol use without cravings.
  • Skeptical group:
    • Worries about long‑term, high‑dose use for weight loss vs older, lower‑dose diabetes regimens.
    • Known issues: nausea, GI effects, rare gastroparesis, possible thyroid cancer signal in animals, muscle/bone loss with rapid weight loss, occasional mood issues.
    • Some expect a future “other shoe dropping,” referencing the history of failed weight‑loss drugs. Others respond that GLP‑1s differ mechanistically and have ~15–20 years of class experience.

Obesity, Personal Responsibility, and Culture

  • Intense debate over “just eat less and exercise” vs biology, environment, and food industry influences.
  • Multiple commenters emphasize that lifestyle advice alone has poor real-world success for significant, sustained weight loss.
  • Others argue culture, food systems, and individual responsibility should be the primary levers, not chronic drug use.

Cost, Access, and Policy

  • High US prices (~$1,000/month) criticized as life‑and‑death gatekeeping, especially given much lower prices abroad.
  • Ideas floated: government patent purchase, compulsory licensing, or “national security” framing; counterpoints note huge acquisition costs and upcoming patent expirations.

Data and Privacy

  • The study’s 116M‑patient EHR dataset is not public; likely comes from commercial aggregators.
  • Some express strong discomfort with large, cloud‑hosted medical data despite HIPAA assurances.